Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
65,095,000
-
Total 13F shares
-
62,196,889
-
Share change
-
+2,670,938
-
Total reported value
-
$280,514,086
-
Put/Call ratio
-
0%
-
Price per share
-
$4.51
-
Number of holders
-
115
-
Value change
-
+$11,963,150
-
Number of buys
-
76
-
Number of sells
-
34
Institutional Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q2 2025
As of 30 Jun 2025,
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) was held by
115 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,196,889 shares.
The largest 10 holders included
NEA Management Company, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BVF INC/IL, Versant Venture Management, LLC, BAKER BROS. ADVISORS LP, BlackRock, Inc., Avoro Capital Advisors LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, and FMR LLC.
This page lists
115
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.